Express Diagnostics News
Express Diagnostics launches the first-ever instant, lateral flow test for EtG
Express Diagnostics Int’l today announced the launch of the first-ever onsite, lateral flow test for Ethyl glucuronide (EtG), a unique biomarker of alcohol use. EtG testing previously has been available only through laboratories, at significant cost and several days in transit and processing. The new DrugCheck® Rapid EtG™ (Patent Pending) urine test delivers accurate, reliable results in as little as one minute, at a fraction of the cost of lab-based EtG tests.
Express Diagnostics initiated development of the DrugCheck Rapid EtG point-of-care test in 2013 and leveraged partnerships globally to be able to offer the test to the U.S. market. It has the potential to be one of the most transformative tests in the industry since the development of instant, onsite drug tests in the 1990s. Express Diagnostics has partnered with a leading firm in the marketing of drugs of abuse testing to facilitate sales and distribution of the DrugCheck Rapid EtG test in the U.S.
“Express Diagnostics is very excited to bring the first-ever onsite, lateral flow EtG test to market. Compared to the typical process, whereby tens of thousands of specimens nationwide are shipped each day for lab-based EtG tests, our new Rapid EtG test offers unheard of flexibility and efficiency for alcohol abstinence monitoring,” says Paul Johnson, CEO of Express Diagnostics. “The tremendous cost and time savings that the DrugCheck Rapid EtG offers administrators will be truly transformative for those organizations currently testing for EtG, not to mention the additional forensic-use markets that will now employ EtG testing due to the superior convenience, accuracy, and speed of this instant test. DrugCheck Rapid EtG is a true ‘game changer’ in onsite testing!”
Alcohol is the most commonly abused substance worldwide, but it is also the most difficult to detect via abstinence monitoring where alcohol consumption is prohibited. Abstinence monitoring is conducted in a range of environments, from criminal justice, probation, and parole, to treatment centers and the military. Because alcohol is rapidly cleared from the body, detection times in traditional alcohol (ethanol) testing are limited to a few hours after use, and therefore of limited use in abstinence monitoring. In contrast, EtG is a unique biological marker of alcohol use that can be detected up to 80 hours after alcohol ingestion.
EtG testing was first offered by laboratories around 2005 and was soon recognized as one of the most significant tools available for abstinence monitoring. While use of EtG testing grew initially, concerns over potential false-positive results from inadvertent, environmental alcohol exposure, such as mouthwash and hand sanitizers, began to limit use of the test. More recent research and development has advanced both the science of EtG testing and the understanding of appropriate cutoffs, or detection levels, for accurate detection of the alcohol biomarker.
The 500 ng/mL cutoff of the new DrugCheck Rapid EtG test is widely considered to be the optimal cutoff for EtG testing for abstinence monitoring. Positive results at the 500 ng/mL threshold for Rapid EtG are consistent with recent ingestion of alcohol — up to approximately 48 hours prior to specimen collection. Studies also indicate that positive results at this cutoff are not associated with incidental alcohol exposure, such as from mouthwash or hand sanitizer.
To perform a test with the DrugCheck Rapid EtG, simply dip the test strip into a urine specimen for 15 seconds. Negative results can be read in as little as one minute. Positive results are interpreted at 5 minutes and are stable for two hours. The test has a shelf life of two years from the date of manufacture.
The DrugCheck Rapid EtG test is for forensic use only and is intended for use only in alcohol abstinence monitoring for law enforcement, including correction centers, court systems, jails, police departments, probation offices, and other law enforcement organizations.
Learn more at drugchecketg.com.
Express Diagnostics launches Drug Abuse Recognition and onsite drug screening system
Express Diagnostics Int’l recently launched the DrugCheck® DAR-OS™ system to integrate Drug Abuse Recognition (DAR) training with utilization of onsite screening for drugs of abuse. The comprehensive system is designed to develop participants’ skills in recognizing drug use and provide the tools necessary to screen onsite for specific drugs.
With DrugCheck DAR-OS, law enforcement organizations can now implement Drug Abuse Recognition and drug detection systems similar to processes currently used in identifying alcohol-related offenses.
“I learned about the benefits of Drug Abuse Recognition early in my law enforcement career,” says Rich Strasser, COO of Express Diagnostics and retired California detective. “The skills taught in the DAR training program assist in identifying drug use and impairment and are a perfect complement to our onsite drugs of abuse tests.”
DrugCheck DAR-OS was developed in partnership with Graves & Associates, a leading provider of certified DAR training. Implementation of the DAR-OS system begins with DAR training conducted by Graves & Associates, including drug physiology and symptomology to identify objective symptoms related to seven drug classifications. DAR training also employs a seven-step process to determine drug influence and provides reasonable suspicion to initiate onsite drug screening with the DrugCheck® SalivaScan™ Oral Fluid Drug Test. DrugCheck DAR-OS and SalivaScan are available for forensic use only.
“Onsite testing is a great resource to detect drug abuse,” says Keith Graves, president of Graves & Associates. “And with the DrugCheck DAR-OS, using onsite testing in conjunction with skills learned through DAR training, law enforcement practitioners can now detect drug influence in addition to specific recent drug use.
“Graves & Associates is excited to partner with Express Diagnostics to offer this innovative new service.”
EDI representatives to speak at End Violence Against Women International’s 2014 conference
Express Diagnostics Int’l, Inc. (EDI) is pleased to announce that representatives from the company will be speaking next week at the 2014 conference of End Violence Against Women International (EVAWI), April 22-24 in Seattle, Wash. Express Diagnostics is also a corporate sponsor for the conference.
“Express Diagnostics is honored to be supporting EVAWI’s conference and their mission,” says Rich Strasser, COO of Express Diagnostics. “As a retired detective from California, I have seen the tragic results of some of the horrific crimes committed against women and I applaud the efforts of Joanne Archambault and everyone at EVAWI for their relentless efforts to train and educate the law enforcement community.”
Strasser and Les Wilson, director of technical resources at EDI, will present “Characteristics of Drugs Used in Drug-Facilitated Sexual Assaults.” The presentation will provide information on the biological effects of substances typically used in drug-facilitated sexual assaults, such as ecstasy, gamma-hydroxybutyric acid (GHB), ketamine, and rohypnol. Strasser and Wilson will also discuss rapid drug-screening devices available to law enforcement that can provide valuable, immediate information in the early stages of a sexual assault investigation.
EVAWI’s vision statement summarizes the goal of the annual conference: “We envision a world where gender-based violence is unacceptable; where perpetrators are held accountable, and victims receive the compassion, support, and justice they deserve.” The three-day conference, titled “International Conference on Sexual Assault, Domestic Violence and Trafficking,” will highlight emerging issues and promising practices that can be implemented by law enforcement personnel, prosecutors, victim advocates, judges, rape crisis workers, and medical personnel.
This year’s sponsorship and presentation marks EDI’s first time participating in the End Violence Against Women International conference. “EVAWI is pleased to welcome Express Diagnostics to present different drug screening technologies available in the investigation of drug-facilitated sexual assaults,” says Joanne Archambault, executive director of EVAWI. “Our largest contingent of conference participants comes from the law enforcement community and this is a great opportunity to get these technologies out to them so they know what tools are available.”
For more details and a full conference agenda, visit evawintl.org.
Express Diagnostics welcomes new controller
Express Diagnostics Int’l, Inc. (EDI) is pleased to welcome Dave Klabunde as controller. In the position, Klabunde will direct EDI’s finance department, as well as serve an advisory role in company-wide financial and business decisions.
Klabunde previously served as financial analyst/controller for Fairmont Orthopedics & Sports Medicine and, prior to that, as program-operations manager at Youth Services International, Inc. (YSI), a residential treatment facility for juveniles. While at YSI, Klabunde was involved in all aspects of the organization’s operations, including operational planning and direction of cross-functional departments, financial planning, and leading human resources information systems and information technology initiatives.
“We are very pleased to have Dave join our team as controller,” says Paul Johnson, CEO of Express Diagnostics. “His extensive background in business and financial planning, as well as his broad operations experience, will be a great asset in clarifying decision points as we progress as a company. Dave will be instrumental in helping management direct our tremendous growth.”
Klabunde started with EDI in early October and looks forward to ‘getting up to speed’ with the various tasks and departments he will be involved with as controller. “I like the business side of controller duties, because numbers don’t lie,” he says. “My role will be to look forward and around what’s going on to allow management to make decisions on the overall direction of the organization.”
Originally from Nebraska, Klabunde has lived in the Blue Earth, Minn., area since 1997. He and his wife, Karen, have three children: Ryanne, 15; Taylor and Matthew, both 8.
Express Diagnostics named to the Inc. 5000 list of fastest-growing companies
Inc. magazine today named Express Diagnostics Int’l, Inc. (EDI) to its annual Inc. 5000 list of the fastest-growing companies in the U.S., with the position of 2,846 on the 2013 Inc. 5000. EDI manufactures and distributes DrugCheck® onsite drugs of abuse tests, as well as a growing line of rapid alcohol screening and health diagnostics devices.
“For 32 years, Inc. has welcomed the fastest-growing private companies in America into a very exclusive club,” says Eric Schurenberg, Inc. editor in chief. “The Inc. 5000 was harder to get into this year than ever in its history. The median company on the list increased sales more than 140 percent since the start of 2010, while the average honoree grew a mind-boggling 468 percent. Those are results most companies could only dream of in the economy of the past three years.”
With its inclusion as an Inc. 5000 honoree, Express Diagnostics Int’l now shares a pedigree with well-known companies such as Intuit, Zappos, Under Armour, Microsoft, Timberland, Pandora, Patagonia, Oracle, and scores of other alumni.
“Express Diagnostics is thrilled to be named to the Inc. 5000,” says Paul Johnson, CEO of EDI. “This honor is the result of sustained dedication of our personnel and loyal customers, as well as the continued commitment of our vendor partners to satisfy the requirements of our ever-increasing volumes. Our substantial growth, particularly over the last three years, truly has been a team effort and EDI management wants to recognize all of those who made this Inc. 5000 honor possible. We look forward to even greater growth in the future with the dedicated, collaborative team that we’ve assembled.”
Express Diagnostics is based in Blue Earth, Minn., and has distribution partners in more than 60 countries. Founded in 2004, EDI also has company representatives in California, Colorado, Massachusetts, Texas, and Strasbourg, France.
About the Inc. 5000
The 2013 Inc. 500 | 5000 is ranked according to percentage revenue growth when comparing 2009 to 2012. To qualify, companies must have been founded and generating revenue by March 31, 2009. They had to be U.S.-based, privately held, for profit, and independent – not subsidiaries or divisions of other companies – as of December 31, 2012. The minimum revenue required for 2009 is $100,000 and $2 million for 2012. Companies on the Inc. 5000 are featured in the magazine’s September issue, and online at the 2013 Inc. 5000 web page.
(top of page)